ERBB2 and adenocarcinoma: According to reports, about ~ 12% to ~ 20% of GC patients are HER2-positive, with rates in the adenocarcinoma of esophagogastric junction (AEG) as high as 32.2%, indicating the requirement for an effective treatment strategy for HER2-positive GC [3, 4].